GLP-1 Receptor Agonists in Breast Cancer: Moving Beyond Weight Loss Toward Cancer Prevention and Survivorship
Key Points
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with reduced breast cancer incidence and may have a role in primary prevention, particularly among women with obesity or elevated risk.
- Real-world and observational data suggest GLP-1RA use is linked to improved overall and recurrence-free survival in patients with breast cancer.
- Evidence presented at ASCO 2026 indicates GLP-1RAs may reduce metastatic progression across multiple malignancies, including breast cancer, and improve select survivorship outcomes such as lymphedema.
- While findings are promising, the benefits of GLP-1RAs remain hypothesis-generating, and prospective randomized trials are needed to determine causality, optimal use, and underlying mechanisms.
Obesity is increasingly recognized as a modifiable risk factor across the breast cancer continuum, influencing cancer incidence, treatment outcomes, recurrence risk, and survivorship.1-3 Excess adiposity promotes chronic inflammation, hyperinsulinemia, altered adipokine signaling, and increased aromatase activity, creating a biologic environment that may support tumor development and progression.4-7 As GLP-1RAs have transformed the management of obesity and type 2 diabetes, attention has shifted toward their potential role in breast cancer prevention and outcomes.
Obesity and Breast Cancer Biology
Initial interest in GLP-1RAs centered on their ability to achieve substantial and durable weight loss. However, emerging evidence suggests these agents may offer benefits beyond metabolic improvement. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, several studies examined the association between GLP-1RA use and breast cancer incidence, survival, lymphedema, metastatic progression, and treatment-related complications, providing some of the strongest evidence to date for further investigation in oncology.
Among women undergoing breast cancer screening, McDonald and colleagues reported that GLP-1RA exposure was associated with a significantly lower incidence of breast cancer after adjustment for age, body mass index, breast density, diabetes status, and demographic factors (OR, 0.75; 95% CI, 0.63–0.88).8 Similarly, Gotera et al. demonstrated a modest but significant reduction in breast cancer incidence among high-risk women with obesity (HR, 0.84; 95% CI, 0.78–0.92), suggesting a potential role for GLP-1RAs in primary prevention.9 In a separate analysis of non-diabetic women with elevated BMI, Shah et al. found that GLP-1RA exposure was associated with lower incidence of HR-positive/HER2-negative breast cancer and improved overall survival (OS), supporting the hypothesis that metabolic interventions may preferentially influence hormone receptor–positive disease.10
GLP-1RAs and Breast Cancer Outcomes
The notable breast cancer outcome data come from a recently published JAMA Network Open study of more than 840,000 women with breast cancer. GLP-1RA use was associated with significantly improved overall and recurrence-free survival among patients with obesity and type 2 diabetes.11 Among patients with obesity, GLP-1RA exposure was associated with a 65% reduction in mortality risk and a 56% reduction in recurrence risk compared with non-users.11 These findings provide important real-world evidence that metabolic therapies may influence long-term cancer outcomes.
Additional ASCO data strengthened this signal across solid tumors. In a large propensity-matched analysis presented by Orland et al., GLP-1RA initiation after stage I–III cancer diagnosis was associated with reduced metastatic progression across multiple malignancies. Significant reductions in progression to stage IV disease were observed in breast cancer, non–small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. In breast cancer, metastatic progression occurred in 10.2% of GLP-1RA-exposed patients compared with 20.1% of matched DPP-4 inhibitor controls, corresponding to a 43% relative reduction in progression risk (HR, 0.57; 95% CI, 0.46–0.71). Notably, complementary analyses of The Cancer Genome Atlas demonstrated that higher tumor GLP-1 receptor expression was independently associated with improved OS, with one of the strongest signals observed in breast cancer (HR, 0.55; 95% CI, 0.35–0.87), providing biologic plausibility for a potential antitumor effect beyond weight loss alone.12
GLP-1RA Survivorship Effects
Beyond recurrence and survival, several ASCO 2026 presentations highlighted survivorship implications. Yesho and colleagues reported a 63% reduction in postmastectomy lymphedema among GLP-1RA users, suggesting potential disease-modifying effects on the lymphatic microenvironment.13 In metastatic HR-positive/HER2-negative breast cancer, Palleschi et al. observed improved OS among patients receiving GLP-1RAs concurrently with endocrine therapy and CDK4/6 inhibitors (HR, 0.70), while Patino et al. found no significant increase in toxicity when GLP-1RAs were administered alongside CDK4/6 inhibitors.14-15
Additional real-world data demonstrated lower hospitalization rates and a trend toward improved survival among patients with breast cancer and type 2 diabetes receiving GLP-1RAs. Emerging preclinical data also suggest a possible cardioprotective role during anthracycline- and HER2-targeted therapy, with semaglutide reducing inflammation, attenuating myocardial injury, and preserving cardiac function in nondiabetic models.16
What Lies Ahead
Despite these encouraging findings, major questions remain unanswered. Are observed benefits driven solely by weight loss and improved cardiometabolic health, or do GLP-1RAs exert direct antitumor effects through immune, inflammatory, endocrine, or metabolic pathways? What is the optimal timing of therapy initiation relative to cancer treatment? Could these agents enhance the efficacy of endocrine therapy or other systemic treatments? How do they affect body composition, sarcopenia, treatment adherence, and quality of life in cancer survivors? Furthermore, while retrospective and real-world datasets consistently suggest improvements in cancer incidence, metastatic progression, and survival, prospective randomized clinical trials are needed to establish causality and identify which patients are most likely to benefit.
The growing body of evidence presented at ASCO 2026 suggests that GLP-1RAs may represent more than weight-loss medications in breast cancer care. Their potential role now spans primary prevention, reduction of metastatic progression, survivorship optimization, and possibly improvement in cancer-specific outcomes. While the current data remain hypothesis-generating, they provide a compelling rationale for prospective clinical trials and mechanistic studies to define how GLP-1RAs may be integrated into the future of breast cancer prevention and treatment.
References
- Nguyen HL, Geukens T, Maetens M, et al. Obesity-associated changes in molecular biology of primary breast cancer. Nat Commun. 2023;14(1):4418. doi:10.1038/s41467-023-39996-z
- Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: A large prospective cohort study. Breast Cancer Res. 2012;14(3):R76. doi:10.1186/bcr3186
- van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514-527. doi:10.1093/aje/152.6.514
- Naaman SC, Shen S, Zeytinoglu M, Iyengar NM. Obesity and breast cancer risk: The oncogenic implications of metabolic dysregulation. J Clin Endocrinol Metab. 2022;107(8):2154-2166. doi:10.1210/clinem/dgac241
- Bhardwaj P, Au CC, Benito-Martin A, et al. Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol. 2019;189:161-170. doi:10.1016/j.jsbmb.2019.03.002
- Boutens L, Hooiveld GJ, Dhingra S, Cramer RA, Netea MG, Stienstra R. Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses. Diabetologia. 2018;61(4):942-953. doi:10.1007/s00125-017-4526-6
- Brown KA. Metabolic pathways in obesity-related breast cancer. Nat Rev Endocrinol. 2021;17(6):350-363. doi:10.1038/s41574-021-00487-0
- McDonald ES, Gillis L, Gabriel P, et al. Association of GLP-1 agonists with breast cancer incidence in women. J Clin Oncol. 2026;44(16_suppl):10506. doi:10.1200/JCO.2026.44.16_suppl.10506
- Gotera NP, Jones C, Gelfond J, et al. GLP-1 receptor agonists for primary prevention of breast cancer in high-risk women: A real-world analysis of efficacy and safety. J Clin Oncol. 2026;44(16_suppl):10520. doi:10.1200/JCO.2026.44.16_suppl.10520
- Shah Z, Hundal J, Afridi SS, et al. GLP-1 therapy and hormone receptor-positive breast cancer risk and survival: A real-world analysis. J Clin Oncol. 2026;44(16_suppl):10548. doi:10.1200/JCO.2026.44.16_suppl.10548
- Tatum KL, Dahman B, Stevenson A, et al. Survival and recurrence with GLP-1 receptor agonists in breast cancer. JAMA Netw Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.
- Orland MD, Mandala A, Unlu S, et al. Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. J Clin Oncol. 2026;44(16_suppl):3143. doi:10.1200/JCO.2026.44.16_suppl.3143
- Yesho DH, Megiso M, Ugwu C, et al. GLP-1 RA for primary prevention of post-mastectomy lymphedema in breast cancer patients: A multicenter real-world analysis. J Clin Oncol. 2026;44(16_suppl):628. doi:10.1200/JCO.2026.44.16_suppl.628
- Palleschi M, Gianni C, Merloni F, et al. Real-world survival benefit of glucagon-like peptide-1 receptor agonists concomitant with cyclin-dependent kinase 4/6 inhibitors and endocrine therapy in hormone receptor-positive/HER2-negative metastatic breast cancer: A large propensity-matched analysis. J Clin Oncol. 2026;44(16_suppl):1070. doi:10.1200/JCO.2026.44.16_suppl.1070
- Patino K, Moore G, Labatut A, et al. Impact of GLP-1 receptor agonists in hormone receptor-positive breast cancer patients receiving CDK4/6 inhibitors. J Clin Oncol. 2026;44(16_suppl):1100. doi:10.1200/JCO.2026.44.16_suppl.1100
- Quagliariello V, Di Mauro A, Ferrara G, et al. Effect of GLP-1 receptor agonism on anthracycline- and HER2-targeted therapy-induced cardiac dysfunction and systemic inflammation in non-diabetic preclinical models. J Clin Oncol. 2026;44(16_suppl):e12524. doi:10.1200/JCO.2026.44.16_suppl.e12524